← TrialMatch
HomeTrials

Written Exposure Therapy for Veterans With SUD and PTSD

The proposed project will evaluate the efficacy of written exposure therapy (WET) among Veterans engaged in substance use disorder (SUD) treatment, who present with co-occurring posttraumatic stress disorder (PTSD). While SUD treatment programs traditionally do not address PTSD, effective trauma treatments have been us

Condition(s)Substance Use Disorders, Posttraumatic Stress Disorder
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThe proposed project will evaluate the efficacy of written exposure therapy (WET) among Veterans engaged in substance use disorder (SUD) treatment, who present with co-occurring posttraumatic stress disorder (PTSD). While SUD treatment programs traditionally do not address PTSD, effective trauma treatments have been used successfully among those with substance use comorbidities. WET is a brief trauma-focused intervention shown to effectively treat PTSD. In a recent acceptability and feasibility pilot study among Veterans with co-occurring SUD and PTSD, results showed a decrease in PTSD symptoms among participants receiving WET. The goal of the present study is to improve outcomes for Veterans who present for SUD treatment with comorbid SUD/PTSD.
Who can participateInclusion Criteria: * Veterans ages 18 years old or older; * Meets DSM-5 criteria for at least one substance use disorder (SUD); * Meets DSM-5 criteria for PTSD; * Approved for SUD treatment at VA Connecticut Healthcare System. Exclusion Criteria: * Veterans who meet current criteria for schizophrenia, schizophrenia-type disorders, or unmedicated mania or bipolar disorder as determined by QuickSCID-5; * current suicidal or homicidal risks necessitating a higher level of care; * Veterans who have received an Evidence-Based Psychotherapy for PTSD protocol within the past 6 months; * Problems that would prevent a participant from completing the writing intervention or study assessments (e.g., illiteracy). To assess for literacy, participants will read parts of the consent out loud.
Ages18 Years
SexAll
Lead sponsorVA Office of Research and Development
LocationsWest Haven, Connecticut, United States
Start date2022-09-26
NCT IDNCT05327504
Official listinghttps://clinicaltrials.gov/study/NCT05327504

🔍 Search all trials →